Last updated: 2026-09-16 10:31:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Co-Diagnostics, Inc. (CODX) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $1.13, with a market capitalisation of $7.75M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.94 to $46.50. This page covers its latest market performance, valuation, price trends and company information.
$7.75M | |
$1.15 | |
$929.70 | |
$0.94 | |
$1.14 | |
4.15K | |
426.39K | |
-- | |
$46.50 | |
$0.94 | |
-- | |
-- |
Co-Diagnostics, Inc. (CODX) is trading at $1.13 in pre-market trading as of 2026-09-16 10:29:00, down 0.88% ($0.01) from the previous close of $1.14
Pre-market trading shows how investors are pricing CODX before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Co-Diagnostics, Inc. (CODX) moved from $1.16 to $1.13, representing a decline of 2.59% ($0.03).
The stock traded between $1.09 and $1.25 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 135.14 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.4%
CODX is currently trading at $1.13, placing it 0.4% of the way from its 52-week low of $0.94 to its 52-week high of $46.50. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 115 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Co-Diagnostics, Inc. (CODX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.